HCPCS Options Galore for Leukemia and Lymphoma Treatments in 2011
This year HCPCS brings for you three new J codes for leukemia and lymphoma treatments. So if you provide Arzerra injections, you should take notice of new code J9302. Normally, oncologists use the medication to treat chronic lymphocytic leukemia in adults who have not responded well to fludarabine or alemtuzumab. This medication is a monoclonal antibody as the suffix -mab in ofatumumab indicates.
Earlier, hospitals had a C code available for this agent, C9260. This year HCPCS deletes this code (these C codes are proper only for Hospital Outpatient Prospective Payment System claims).
This year, you'll have one more J code for Folotyn. Oncologists normally use this folate analogue metabolic inhibitor to kill cancer cells in patients with peripheral T-cell lymphoma that hasn't responded to other medications or has returned.
Apart from these, this year you will also not find C code available to hospitals for this drug, C9259 as HCPCS 2011 deletes it.
And if your documentation shows your practice supplied Istodax, you have J9315 at your service this year.
This drug is a histone deacetylase inhibitor that slows the growth of cancer cells and is intended for use in patients with cutaneous T-cell lymphoma who have been treated previously with another drug.In 2010, hospitals had used C9265 (Injection, romidepsin, 1 mg) for this drug; however HCPCS 2011 deletes it.
For a quick glance at these HCPCS code changes this year and for other changes as far as these codes are concerned, sign up for a one-stop medical coding guide like Supercoder.
barcelona vs real madrid hepatitis c lenny dykstra yacht the conspirator